Cancer shifts constantly

  • Adjuvant
  • Recurrance
  • Advanced
  • Progression

Completely transform the way you see what’s next, now.

  • Adjuvant
  • Recurrance
  • Advanced
  • Progression

Guardant Complete is a portfolio of revolutionary liquid and tissue precision oncology tests, all with the convenience of a single testing company.1,2


Guardant Reveal™ is the first liquid-only minimal residual disease
(MRD) detection test with
high landmark sensitivity at 4 weeks post-surgery to help with therapy decisions in early-stage patients with colorectal cancer (CRC).3,4


Guardant Reveal™ is the first liquid-only MRD detection
test with up to 91% sensitivity to help detect recurrence in colorectal cancer (CRC) surveillance.3,4


Guardant360® CDx is the first
FDA-approved liquid CGP
(comprehensive genomic profiling) with results in
7 days to help optimize treatment selection quickly.1,5

Guardant360® CDx is the first FDA-approved liquid CGP (comprehensive genomic profiling) with results in 7 days to help optimize treatment selection quickly.1,5

Guardant360 TissueNext™ is a Medicare-covered tissue CGP with an AI-powered scoring algorithm that improves PD-L1 detection by >20% in non-small cell lung cancer, if ordered.2,6


Guardant360® is a liquid CGP test with an expanded panel that enables you to identify additional treatment options for your progressing patients.7,8

Guardant360 Response™ is a liquid-only assessment of molecular response that predicts treatment response 8 weeks earlier than standard imaging.9,10

Guardant Complete leads the way in precision oncology testing.

Our proprietary, cutting-edge technology measures changes in circulating tumor DNA (ctDNA) to1:

  • +

    Get a highly sensitive, minimally invasive
    assessment of cancer11

  • +

    Detect spatial and temporal evolution of a tumor12

The Guardant Complete
portfolio is backed by data from:

>300,000patients tested

>80 clinical outcomes

>350 peer-reviewed

A wide array of precision oncology assays and comprehensive support, all conveniently accessible in one, intuitive portal.

Partner with Guardant Complete and experience seamless
customer service, including:

  • +

    One intuitive portal to conveniently order
    all tests

  • +

    End-to-end billing assistance with Guardant Access

  • +

    Mobile phlebotomy for convenient sample collection

  • +

    On-demand support from Guardant Health Medical Affairs

Guardant Complete can transform how
you make critical treatment decisions
across the cancer continuum.3,9


Guardant Reveal Logo

First liquid-only biopsy for minimal residual disease (MRD) detection in early-stage settings.3

Explore product ›
FDA Approved Guardant360 CDx Logo

First FDA-approved liquid-only comprehensive genomic profiling (CGP) for advanced-stage treatment selection.1,5

Explore product ›
Guardant360 TissueNext Logo

Tissue CGP for advanced-stage
treatment selection.2

Explore product ›
Guardant360 Response Logo

Liquid-only biopsy that measures treatment response in advanced-stage cancer.9

Explore product ›
Guardant360 Logo

Liquid-only CGP test for treatment selection in patients who have progressed on therapy.7

Explore product ›

Important Note: Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 tests were developed, and performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 are Laboratory Developed Tests (LDT). These tests have not been cleared or approved by the US FDA.

*Patient timeline is for illustrative purposes only.

Confirmation of medical necessity is required if Guardant360 TissueNext is ordered with another Guardant Health profiling test.

HRR, homologous recombinational repair; MSI, microsatellite instable; NTRK, neurotrophic tyrosine receptor kinase; PD-L1, programmed death-ligand 1; TMB, tumor mutation burden.

References: 1. Guardant360® CDx Technical Information. Guardant Health, Inc. Palo Alto, CA. July 2021. 2. Guardant360 TissueNext™ Assay Specifications. Guardant Health, Inc. Palo Alto, CA. 3. Backgrounder: Guardant Reveal™ liquid biopsy test. Guardant Health, Inc. Palo Alto, CA. 4. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410 5. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7, 2020. Accessed October 31, 2022. 6. Guardant Galaxy Flyer. Guardant Health, Inc. Palo Alto, CA. 7. Guardant360® Assay Specifications. Guardant Health, Inc. Palo Alto, CA. 8. Cui W, Milner-Watts C, O'Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012 9. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047 10. Guardant360® Response: Guide to ordering Guardant360 Response. Guardant Health, Inc. Palo Alto, CA. 11. Shields MD, Chen K, Dutcher G, Patel I, Pellini B. Making the rounds: exploring the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer. Int J Mol Sci. 2022;23(16):9006. doi:10.3390/ijms23169006 12. Gilson P, Merlin JL, Harlé A. Deciphering tumour heterogeneity: from tissue to liquid biopsy. Cancers (Basel). 2022;14(6):1384. doi:10.3390/cancers14061384